Active substanceAdemethionineAdemethionine
Similar drugsTo uncover
  • Ademethionine-Vial
    pills inwards 
    VIAL, LLC     Russia
  • Heparetta®
    lyophilizate w / m in / in 
    TRIVIUM-XXI, LLC     Russia
  • Heptor
    pills inwards 
    VEROPHARM SA     Russia
  • Heptor
    lyophilizate w / m in / in 
    LENS-PHARM, LLC     Russia
  • Heptor H
    pills inwards 
    VEROPHARM SA     Russia
  • Heptransan
    lyophilizate w / m in / in 
    IRVIN 2, LLC     Russia
  • Heptransan
    pills inwards 
    IRVIN 2, LLC     Russia
  • Heptral®
    lyophilizate w / m in / in 
    Abbott Sr.L.     Italy
  • Heptral®
    pills inwards 
    Abbott Sr.L.     Italy
  • Heptral®
    pills inwards 
  • Dosage form: & nbspenteric coated tablets
    Composition:

    One tablet contains

    Active substance: Ademethionine tosylate disulfate in terms of ademetionine ion - 400 mg.

    Auxiliary substances to obtain a tablet weighing 0.95 g (excluding shell): Polyplasdon X-El-10 (crospovidone) - 19 mg, microcrystalline cellulose - 53 mg, Mannitol (mannitol) - 53 mg, magnesium stearate - 15 mg.

    Auxiliary substances sufficient amount to obtain a tablet with a coating weight of 1.045 g: acryl-from yellow - [methacrylic acid and ethylacrylate copolymer (1: 1), talc, titanium dioxide, silicon dioxide colloid, triethyl citrate, sodium hydrogen carbonate, sodium lauryl sulfate, iron oxide yellow, quinoline yellow aluminum lacquer], hydroxypropylmethylcellulose, plasdon ES-630 (copovidone), polyethylene glycol 6000.

    Description:

    Tablets covered with an enteric-soluble coat of yellow color, oblong, biconvex.

    Pharmacotherapeutic group:Hepatoprotective agent
    ATX: & nbsp

    A.16.A.A.02   Ademethionine

    Pharmacodynamics:

    Heptor belongs to the group of hepatoprotectors with antidepressant activity. Has choleretic and cholekinetic effect. Has detoxification, regenerating, antioxidant, antifibrozing and neuroprotective action.

    Replenishes the deficit of ademetionine and stimulates its production in the body, primarily in the liver and brain. Participates in biological reactions of transmethylation (a methyl group donor) - a molecule S-adenosyl-Lmethionine (ademethionine) donates the methyl group in the reactions of methylation of phospholipids of cell membranes, proteins, hormones, neutromediators, etc .; transsulfation - the precursor of cysteine, taurine, glutathione, (provides oxidation-reduction mechanism of cellular detoxification), coenzyme A. Increases glutamine content in the liver, cysteine ​​and taurine in plasma; reduces the content of methionine in the blood serum, normalizing metabolic reactions in the liver.After decarboxylation, it participates in aminopropylation processes as a precursor of polyamines - putrescine (stimulator of cell regeneration and proliferation of hepatocytes), spermidine and spermine, which are part of the structure ribosomes. Has a choleretic effect due to increased mobility and polarization of hepatocyte membranes due to stimulation, synthesis of phosphatidylcholine in them. This improves function associated with the membranes of hepatocytes transport systems of bile acids and promotes the passage of bile acids into the bile excretory system. Effective with intraloble variant of cholestasis (a violation of synthesis and current of bile). It contributes to the detoxification of bile acids, increases the content of conjugated and sulfated bile acids in hepatocytes. Conjugation with taurine increases the solubility of bile acids and their removal from hepatocytes. The process of sulphation of bile acids contributes to their elimination by the kidneys, facilitates passage through the hepatocyte membrane and excretion with bile. In addition, sulfated bile acids protect the liver cell membranes from the toxic effect of non-sulphated bile acids present in high concentrations in hepatocytes with intrahepatic cholestasis.In patients with diffuse liver disease (cirrhosis, hepatitis) with intrahepatic cholestasis syndrome reduces the severity of skin itching and changes in biochemical parameters, incl. concentration of direct and total bilirubin, activity of alkaline phosphatase, g-glutamyltranspeptidase, aminotransferases. Choleretic and hepatoprotective effects persist up to 3 months after discontinuation of treatment. Efficacy is shown for hepatopathies due to hepatotoxic drugs. The appointment of ademetionine to patients with opioid addiction, accompanied by liver damage, leads to regression of clinical manifestations of abstinence, improvement of the functional state of the liver and the processes of microsomal oxidation. Antidepressant activity manifests itself gradually, beginning at the end of 1 week of treatment and stabilizing within 2 weeks of treatment. Effective in recurrent endogenous and neurotic depressions resistant to amitriptyline. Has the ability to interrupt recurrence of depression. The appointment in osteoarthritis reduces the severity of the pain syndrome, increases the synthesis of proteoglycans and leads to partial regeneration of the cartilaginous tissue.

    Pharmacokinetics:Bioavailability for ingestion - 5%. With a single intake of 400 mg the maximum concentration in the plasma (Cmah) - 0.7 mg / l. Time to reach the maximum concentration (TCmah) -2-6 h. Binding to plasma proteins is insignificant, it penetrates the blood-brain barrier. With admission, there is a significant increase in the concentration of ademetionine in the cerebrospinal fluid. Metabolised in the liver. Half-life (T1/2) - 1.5 h.
    Indications:

    - chronic non-calculous cholecystitis;

    - cholangitis;

    - intrahepatic cholestasis;

    - Hepatitis of various genesis: viral, toxic, incl. alcohol and medicinal origin (antibiotics, antineoplastic, antituberculous and antiviral drugs, tricyclic antidepressants, oral contraceptives);

    - fatty degeneration of the liver;

    - cirrhosis of the liver;

    - encephalopathy, incl. associated with hepatic insufficiency (alcoholic, etc.)

    - depression (including secondary);

    - abstinence syndrome (alcoholic, etc.).

    Contraindications:

    Hypersensitivity.

    Children under 18 years.

    Pregnancy I-II trimester, lactation.

    Pregnancy and lactation:

    The drug is contraindicated in I-II trimester of pregnancy and lactation.

    Dosing and Administration:

    In the period of maintenance therapy, a daily dose of 800-1600 mg (2-4 tablets) is recommended. The duration of maintenance therapy is on average 2-4 weeks. Tablets should be swallow whole, without chewing. To improve the therapeutic effect of tablets it is recommended to take in the morning between meals.

    Side effects:

    For this dosage form:

    From the nervous system: headache, insomnia.

    On the part of the digestive system: abdominal pain, diarrhea, dryness of the oral mucosa, dyspepsia, flatulence, nausea.

    Overdose:

    There were no clinical cases of overdose.

    Interaction:Interaction with other drugs was not observed.
    Special instructions:
    Precautions for use
    Given the tonic effect of the drug, it is not recommended to take before bed. Oral administration of the drug to patients with liver cirrhosis associated with hyperosotemia should be performed under the supervision of a physician with nitrogen control. The tablets of the preparation are covered with a special coating that dissolves only in the intestine, ademethionine is released in the duodenum. In patients with bipolar affective disorder, ademetionine administration can induce an affect inversion (development of hypomania or mania).
    Effect on the ability to drive transp. cf. and fur:When used in this dosage form, the drug does not affect the ability manage the car and work with mechanisms.
    Form release / dosage:Intestinal-coated tablets, 400 mg
    Packaging:

    10 tablets per contour cell pack.

    For 20,40 or 50 tablets in a can of polymer.

    Each jar or 1, or 2 contour mesh packages together with instructions for use in the pack.

    Storage conditions:

    List B. In a dry, the dark place at a temperature of no higher than 25 ° C. Keep out of the reach of children.

    Shelf life:

    2 years. Do not use after the expiration date.

    Terms of leave from pharmacies:On prescription
    Registration number:LS-001820
    Date of registration:22.08.2011 / 17.09.2015
    Expiration Date:Unlimited
    The owner of the registration certificate:VEROPHARM SA VEROPHARM SA Russia
    Manufacturer: & nbsp
    Information update date: & nbsp02.04.2017
    Illustrated instructions
      Instructions
      Up